NCT02607332已完成2 期
A Trial of Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Disease control rate
研究概览
简要总结
With discovery of KIT mutations and the advent of KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), there has been substantial improvement in overall survival in patients with advanced and/or metastatic gastrointestinal tumors (GIST). Recently, sunitinib (SuteneTM, Pfizer) showed activity as second-line therapy in GIST patients after failure with imatinib. However, virtually all patients will eventually progress or become intolerable after the first-line imatinib and the second-line sunitinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 20 years or older
- •Histologically confirmed metastatic and/or advanced GIST with CD117(cluster of differentiation 117)(+), DOG-1(+), or mutation in KIT or PDGFRα gene(Platelet Derived Growth Factor Receptor)
- •Failed (progressed and/or intolerable) after prior treatments for GIST, including at least both imatinib and sunitinib .
- •Eastern Cooperative Oncology Group performance status of 0~2
- •Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-Common Toxicity Criteria for Adverse Effects version 3.0
- •At least one measurable lesion as defined by Response Evaluation Criteria In Solid Tumors version 1.0
- •Adequate bone marrow, hepatic, renal, and other organ functions
- •Neutrophil > 1,500/mm3
- •Platelet > 100,000/mm3
- •Hemoglobin > 8.0 g/dL
- •Total bilirubin < 1.5 x upper limit of normal (ULN)
- •Aspartate aminotransferase /Alanine transferase< 2.5 x ULN (or < 5 x ULM in case of liver metastases)
- •Creatinine < 1.5 x ULN
- •Life expectancy > 12 weeks
- •Washout period of previous TKIs(Tyrosine Kinase Inhibitor) or chemotherapy for more than 4 times the half life.
- •Provision of a signed written informed consent
排除标准
- •Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control.
- •have the presence of cardiac disease,including a myocardial infarction within 6 months prior to study entry,Clinically significant cardiac disease (New York Heart Association, Class III or IV) or severe unstable angina pectoris, stroke or transient ischemic attack, Arrhythmia in need of treatment
- •Uncontrolled infection
- •Diabetes mellitus (insulin dependent or independent disease, requiring chronic medication) with signs of clinically significant peripheral vascular disease.
- •Acute and chronic liver disease and all chronic liver impairment.(Patients with stable and chronic viral hepatitis are eligible are acceptable)
- •Uncontrolled gastrointestinal toxicities with toxicity greater than NCI Common Toxicity Criteria for Adverse Effects grade 2
- •Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality.
- •The patient experienced any bleeding episode considered life-threatening, or any grade 3 or 4 bleeding event.
- •Major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy.
- •Known diagnosis of HIV infection .
- •History of another primary malignancy that is currently clinically significant or currently requires active intervention.
- •Patients with brain metastases as assessed by radiologic imaging
- •Alcohol or substance abuse disorder.
研究组 & 干预措施
Paclitaxel
Experimental
paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Disease control rate
时间窗: Up to 3 years
次要结局
未报告次要终点
研究者
Yoon-Koo Kang
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258Gastrointestinal Stromal TumorsNCT01440959Asan Medical Center30
招募中
2 期
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.Gastrointestinal Stromal TumorsNCT03944304Asan Medical Center40
终止
2 期
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell CancerTesticular CancerNCT02478502University Hospital, Akershus14
已完成
3 期
Study of ABI-007 and Taxol in Patients With Metastatic Breast CancerBreast NeoplasmsMetastases, NeoplasmNCT00046527Celgene Corporation460
撤回
1 期
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyFallopian Tube CancerEpithelial Ovarian CancerPrimary Peritoneal CarcinomaNCT03607955Washington University School of Medicine